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Somemedical scientists argue that only data from random-
ized controlled trials (RCTs) are trustworthy. They claim
data fromnatural experiments andadministrative data sets
are always spurious and cannot be used to evaluate health
policies and other population-wide phenomena in the real
world. While many acknowledge biases caused by poor
study designs, in this article we argue that several valid
designs using administrative data can produce strong find-
ings, particularly the interrupted time series (ITS) design.
Many policy studies neither permit nor require an RCT for
cause-and-effect inference. Framing our arguments using
Campbell and Stanley’s classic research design mono-
graph, we show that several Bquasi-experimental^ designs,
especially interrupted time series (ITS), can estimate valid
effects (ornon-effects) of health interventions andpolicies as
diverse as public insurance coverage, speed limits, hospital
safety programs, drug abuse regulation and withdrawal of
drugs from the market. We further note the recent rapid
uptake of ITS and argue for expanded training in quasi-
experimental designs in medical and graduate schools
and in post-doctoral curricula.
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Information in administrative data sets is spurious by
default.
John Ioannidis1
This statement prolongs the polarizing debate on the trust-
worthiness and reproducibility of findings from Bavailable
data.^2–4 We disagree that observational data are always spu-
rious.5 While many weak observational studies are biased,6
many valid designs using administrative data produce trust-
worthy findings. Moreover, RCTs can be infeasible, invalid or
not generalizable despite being the Bgold standard.^ Study end
points are manipulated, or patients may not be blind to their
treatment, resulting in placebo effects or exaggerated beliefs in
the study treatment. Furthermore, RCTs are only useful for a
fraction of health interventions, such as drugs and medical
technologies.7–9 In addition to national policies, real-life events
create other unparalleled research opportunities, e.g., govern-
ment seatbelt laws, banishing certain drugs from the market,
changing highway speed limits,10 high deductible health insur-
ance,11 changes or extreme spikes in the cost of drugs,12,13
antibiotic controls,14 health outcomes of the UK’s pay-for-
performance program,15 anti-indoor smoking regulations,5 and
outcomes of state regulation of psychoactive drug use.16 These
policies produced important health effects, including changes in
mortality, that cannot be studied experimentally.
THE INNOVATION OF QUASI-EXPERIMENTATION
In 1963, Campbell and Stanley, published their landmark text,
BExperimental and Quasi-Experimental Designs for
Research,^17 revised thereafter in 1979 and 2002.5,18 They
showed several quasi-experimental research designs were of-
ten resistant to the main threats to validity such as secular
trends or history bias (e.g., pre-intervention improvements in
acute MI care), selection bias (e.g., study groups already
healthier than controls), etc.17 This and other texts on quasi-
experimental designs have expanded the acceptance of non-
experimental studies.5,17–19
Campbell and Stanley described three main categories of
research design:
1. Randomized Experiments: These Bgold-standard^ de-
signs randomly allocate patients or clusters (e.g., health
centers) to intervention and control groups. Assuming an
adequate sample size, randomization addresses most
sources of selection bias and confounding. However,
randomized trials can still mislead if they are too small,
non-representative or not really double blind.
2. Strong quasi-experiments: These designs compare
changes in outcomes before and after a study intervention
with changes in a comparable control group. Variations
include: (1) comparisons of changes in hospitalization
rates after a drug safety program with simultaneous
changes in multiple control groups20 and (2) interrupted
time series with or without control group(s) that measure
abrupt changes from baseline trends (e.g., sudden
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increases in the level or slope of emergency room
admissions among the chronically mentally ill soon after
a cap on public insurance benefits).21
3. Weak Bpre-experiments,^17: This group of untrustwor-
thy studies is not included in Cochrane systematic
evidence reviews of changes in health policies or
programs,22 e.g., single observations before and after an
intervention without any controls or simple cross-
sectional designs that merely correlate having an
intervention with mortality at a single point in time.23–
25 These study designs cannot distinguish intervention
effects from what would have occurred in the absence of
the intervention [e.g., they do not address the reality that
more profitable and prestigious hospitals are more likely
than others to invest the vast sums required for electronic
health records (EHRs)]. Such studies have influenced
policymakers to spend trillions of dollars on health IT
technologies with few demonstrated health benefits.26–28
Table 1 provides a simple hierarchy of common strong and
weak designs.6,29
INTERRUPTED TIME SERIES (WITH OR WITHOUT A
CONTROL GROUP): EXAMPLES OF A QUASI-
EXPERIMENTAL DESIGN
Interrupted time series designs allow researchers to con-
trol for baseline secular trends, observe a sudden effect of
an intervention (a change in level or slope) and assess the
stability of the change over time.30 The design is strongest
when researchers can follow another group of patients
who have not experienced the intervention, i.e., a control
or Bcomparison series.^ Accessible descriptions of ITS
methods are numerous.7,30–32
Even without a perfect comparison group, ITS can be
causally persuasive. Figure 1 below shows the effect of a
sudden state-imposed Medicaid three-drug reimbursement
limit that restricted medications among chronically ill poor
patients with cardiac and other chronic illnesses.33 Medication
use plummeted immediately by half.
When advocacy organizations sued for damages, the
state suddenly replaced the regulation with a less draco-
nian $1 copayment per prescription after about a year.
Table 1 Hierarchy of Strong and Weak Designs, Based on Capacity to Control for Biases
Strong Design: Often Trustworthy Effects
,ecnedivefo”dradnatsdlog“ehTsTCRelpitluM
incorporating systematic review 
of all RCTs of an intervention 
(e.g., random assignment of 
smoking cessation treatment). 
dezimodnargnorts,elgnisATCRelgniS
experiment, but sometimes not 
generalizable. 
Interrupted time series with 
control series 
Baseline trends often allow 
visible effects and control for 
biases. This design has two 
controls: baseline trend and 
control group to measure sudden 
discontinuities in trend soon 
after an intervention. 
Intermediate designs: Sometimes Trustworthy Effects
Single interrupted time series Controls for trends, but no 
comparison group (see above). 
Before and after with 
comparison group
Pre-post change using single 
observations. Comparability of 
baseline trend often unknown. 
Weak Designs: Rarely Trustworthy Effects (No Controls for Common 
Biases. Excluded from Literature Syntheses) 
Uncontrolled before and after 
(pre-post)
Simple observations before and 
after intervention, no baseline 
trend or control group. 
Cross-sectional designs Simple correlation, no baseline, 
no measure of change. 
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Immediately, the slope of prescription use increased to just
below pre-cap levels. The off-on-off design and immedi-
ate, marked changes in the levels and slopes of the trend
over 48 monthly observations do not allow or require an
RCT to infer cause and effect. The graph of the longitu-
dinal data is Bworth a thousand p-values^. Government
documents also reveal no Bco-interventions^ (simulta-
neous policies that could cause the outcome) and threaten
the validity of such ITS designs.
Even more important to policy and economic analysis,
later time-series studies visibly showed that the sudden
loss of medication access substantially increased institu-
tionalization of frail elders and increased acute mental
health care use among the severely mentally ill. The cost
of hospitalization and nursing home admissions dwarfed
the drug savings.21,34 Indeed, the clearly observable ITS
findings strongly contributed to many health policy im-
provements in the US and other countries, including
rejections by many states of strict limits on drug cover-
age for vulnerable populations, expansion of state-funded
pharmacy assistance programs,35 and the establishment of
subsidies to drug coverage under Medicare Part D.36
ITS can also debunk claimed or false Beffects^ via elegant
and parsimonious illustrations. Figure 2 demonstrates that
hospital mortality was not really affected by the nationwide
(US) hospital safety program of the Institute for Healthcare
Figure 1 Times series effects of changes in drug benefit limits and cost sharing on the average number of constant-size prescriptions per
continuously eligible patient per month among noninstitutionalized New Hampshire patients receiving multiple drugs (n = 860) and other
outpatients (n = 8002)33
Figure 2 Example of a strong time-series design that controlled for history bias in the Institute for Healthcare Improvement’s (IHI) 100,000 lives
campaign. Exhibit is based on data from the Agency for Healthcare Research and Quality (HCUP, 2015).6
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Improvement. The reported mortality decrease appears to
evaporate when examined in relation to the ongoing secular
trend: a fancy way of saying the investigators did not control
for baseline decreases in mortality (history bias) and only
focused on post-intervention data.6 No statistics are needed
to seriously question the claims of 122,000 lives saved. Using
only administrative data without a control group, it is clear the
decline was already happening.
Figure 3 shows increased fatal and injurious car crashes on
Arizona highways with a new 65MPH vs. a previous 55MPH
speed limit. It is an especially powerful example of ITS
because the study group data come from only those highways
with posted higher speed limits reflecting the new law. The
large andmarked upward shift immediately after the change in
speed limit is obvious. In fact, Fig. 3 also displays fatal and
injurious car crashes on AZ highways that did not increase the
posted speed limits. In this graph there is no sudden shift in
fatal and injurious car crashes. No RCT would be feasible in
such a study, and the ITS and control group provide strong
data on the impact of this new law.
Often the most powerful evidence is a graph that simply and
reliably shows the trend and the effects of an intervention.
While not infallible, ITS designs can often supplement, repli-
cate or replace some RCTs.7
DISCUSSION
Between 1996 and 2015, the number of studies in PubMed
identified as Binterrupted time series^ increased from 12 to
Figure 3 Upper graph shows fatal and injurious crashes on Arizona interstate highways with the increase to 65 MPH maximum speed limit.
The lower graph indicates fatal and injurious crashes on Arizona interstate highways with no change in the 55 MPH maximum speed limit10
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239 per year. Even this jump substantially undercounts such
studies because many are described simply as Btime series.^
We hope the increasing use of this common and useful design
is accompanied by an expanding acceptance of other strong non-
experimental designs by medical journals and scholars.5 As
teachers we have an obligation to explain quasi-experiments to
future medical researchers, along with the difference between
strong and weak research designs in evaluating system-wide
innovations affecting health. RCTs can only address a small
proportion of interventions affecting the cost, quality and out-
comes of medical and health policy interventions.
Given the influence research can have on policy, it is
distressing that so much research is untrustworthy because of
faulty research designs. This unease is the subject of a recent
article in the US Centers for Disease Control’s Preventing
Chronic Disease entitled, BHow do you Know Which Health
Care Effectiveness Research You Can Trust? A Guide to Study
Design for the Perplexed^6 http://www.cdc.gov/pcd/issues/
2015/15_0187.htm. Similarly, the National Institutes of Health
(NIH) are deeply concerned about the phenomenon of Bthe
non-reproducibility of research.^37
Research design is often missing in the medical curriculum.
Poorly controlled studies are the rule, not the exception.38 This
confuses the public, policymakers, media and researchers
themselves. The countless reports (and reversals of findings)39
regarding micronutrients and physical activities that grossly
exaggerate lives saved is a case in point.39 Accompanying the
increase in what is viewed as flip-flopping research, we see a
marked rise in media and researcher websites devoted to
uncovering what is viewed as biased or fraudulent research.
Research design may well be the first consideration in ad-
dressing the trustworthiness of research findings.6 Medical and
graduate school curricula should emphasize the weaknesses of
uncontrolled or cross-sectional designs and should include both
experimental and strong quasi-experimental designs. Well-
controlled and -designed studies can save lives,40 while biased
ones promote inefficient expenditures for useless programs,
cause patient safety dangers and suffering, and jeopardize public
health.6
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